These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16335472)

  • 1. A PK primer. How your body processes the drugs you take.
    Horn T
    Posit Aware; 2005; Spec No():4-8. PubMed ID: 16335472
    [No Abstract]   [Full Text] [Related]  

  • 2. What's pk (pharmacokinetics) got to do with it? Supplement introduction.
    Clay PG
    Posit Aware; 2005; Spec No():2-3. PubMed ID: 15828100
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creating a friendly environment for your HIV medications. The effect of interactions.
    Zive JL; Learned J
    Posit Aware; 2005; Spec No():16-21. PubMed ID: 16335474
    [No Abstract]   [Full Text] [Related]  

  • 5. Helping your antiretrovirals help you. Things to consider when choosing what goes in the tank.
    Ngo M
    Posit Aware; 2006; Spec No():15-8. PubMed ID: 17233081
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV drug resistance and you. Resistance testing in experienced patients. Considerations when changing drugs.
    Posit Aware; 2006; Spec No():17-22. PubMed ID: 16596730
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiretroviral drug-drug interaction considerations for HIV-infected children.
    Fletcher CV
    Pediatr Infect Dis J; 2009 May; 28(5):429-30. PubMed ID: 19395949
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug-nutrient interactions and HIV.
    Maurice J
    Posit Aware; 2002; 13(4):38-9. PubMed ID: 12171042
    [No Abstract]   [Full Text] [Related]  

  • 9. Trends in HIV care, Part 2: antiretrovirals in the pipeline, HIV/hepatitis C virus coinfection, and pharmacokinetics of treatment adherence--a roundtable discussion.
    Corales RB; Djeloski DS; Mancenido MD; Valenti WM
    AIDS Read; 2009 Feb; 19(2):62-4, 70-4, 78. PubMed ID: 19271330
    [No Abstract]   [Full Text] [Related]  

  • 10. Unsuspected and paradoxical potential for drug interaction by rifampin: things to ponder with antiretroviral therapy.
    Srinivas NR
    J Infect Dis; 2009 Mar; 199(5):766-7; author reply 767. PubMed ID: 19210166
    [No Abstract]   [Full Text] [Related]  

  • 11. [Advance on targets and drugs for anti-HIV].
    Wang X; Ma H; Wen R
    Zhongguo Zhong Yao Za Zhi; 2009 Jun; 34(11):1454-9. PubMed ID: 19771882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
    AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
    [No Abstract]   [Full Text] [Related]  

  • 13. Can it get even better than this? You don't need to trade in for a newer model-you can live longer and better...while controlling HIV.
    Smigelski C
    Posit Aware; 2006; Spec No():19-21. PubMed ID: 17233082
    [No Abstract]   [Full Text] [Related]  

  • 14. Your health in the 21st century. Keeping HIV at bay.
    Juarez V
    Newsweek; 2005; 145(26A):31. PubMed ID: 16375139
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV treatment and the nonclinician: getting your bearings.
    HRSA Careaction; 2007 Jan; ():1-12. PubMed ID: 17380596
    [No Abstract]   [Full Text] [Related]  

  • 16. When to switch depends on what you can switch to.
    Huff B
    GMHC Treat Issues; 2005; 19(9-11):16. PubMed ID: 16541507
    [No Abstract]   [Full Text] [Related]  

  • 17. [Resistance screening].
    Sierra S; Lengauer T; Kaiser R
    MMW Fortschr Med; 2009 Apr; 151(18):72, 74-5. PubMed ID: 19769083
    [No Abstract]   [Full Text] [Related]  

  • 18. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 19. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
    Panhard X; Legrand M; Taburet AM; Diquet B; Goujard C; Mentré F;
    Eur J Clin Pharmacol; 2007 Nov; 63(11):1019-29. PubMed ID: 17694300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HIV therapy in childhood. Also once daily lopinavir/r is effective].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():55. PubMed ID: 16385877
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.